Anticholinergic drugs for adult neurogenic detrusor overactivity: A systematic review and meta-analysis

European Urology

Volumn 62, Issue 5, 2012, Pages 816-830

  Madhuvrata, Priya ^a   Singh, Manju ^a   Hasafa, Zaid ^b   Abdel Fattah, Mohamed ^c  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Anticholinergics; Antimuscarinics; Detrusor hyperreflexia; Neurogenic bladder; Neurogenic detrusor overactivity

Indexed keywords

ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; FLAVOXATE; MELADRAZINE; METHANTHELINE BROMIDE; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

BLADDER CONTRACTION; BLADDER PRESSURE; CYSTOMETRY; DRUG DOSE COMPARISON; HUMAN; META ANALYSIS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; URODYNAMICS; XEROSTOMIA;

ADULT; CHI-SQUARE DISTRIBUTION; CHOLINERGIC ANTAGONISTS; HEALTH CARE COSTS; HUMANS; ODDS RATIO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84866774979     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.02.036     Document Type: Review

References (38)

1. P. Abrams, L. Cardozo, M. Fall Standardisation Sub-committee of the International Continence Society The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
2. M.B. Chancellor, R.U. Anderson, and T.B. Boone Pharmacotherapy for neurogenic detrusor overactivity Am J Phys Med Rehabil 85 2006 536 545
3. Pannek J, Stöhrer M, Blok B, et al. Guidelines on neurogenic lower urinary tract dysfunction. Arnhem, the Netherlands: European Association of Urology.; 2011.
4. B. Amend, HennenlotterJ, and T. Schäfer Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects Eur Urol 53 2008 1021 1028
5. A.P. Cameron, J.Q. Clemens, and J.M. Latini Combination drug therapy improves compliance of the neurogenic bladder J Urol 182 2009 1062 1067
6. A. Liberati, D.G. Altman, and J. Tetjlaf The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 2009 65 94
7. B.J. Biggerstaff, and R.L. Tweedie Incorporating variability in estimates of heterogeneity in the random effects model in meta-analysis Stat Med 16 1997 753 768
8. Abrams P, Jackson S, Mattiason K, et al. A randomised, double blind, placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia [abstract]. Presented at: 26th annual meeting of the International Continence Society; August 27-30, 1996; Athens, Greece.
9. J. Bycroft, B. Leaker, and S. Wood The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury Neurourol Urodyn 22 2003 A190
10. S.M. Di Stasi, A. Giannantoni, and G. Vespasiani Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens J Urol 165 2001 491 498
11. S.M. Di Stasi, A. Giannantoni, and P. Navarra Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin J Urol 166 2001 2232 2236
12. K.D. Ethans, P.W. Nance, and R.J. Bard Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity Spinal Cord Med 27 2004 214 218
13. M. Fader, S. Glickman, and V. Haggar Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial J Urol 177 2007 208 213
14. J.B. Gajewski, and S.A. Awad Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia J Urol 135 1986 966 968
15. S. Hebjorn Treatment of detrusor hyperreflexia in multiple sclerosis; a double blind, crossover trial comparing methantheline bromide, flavoxate chloride and meladrazine tartarate Urol Int 32 1977 209 217
16. H. Madersbacher, M. Stöhrer, and R. Richter Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia Br J Urol 75 1995 452 456
17. D. Mazur, K. Gocking, and J. Wehnert Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence: a multicentre dose-optimizing study [in German] Urologe - Ausgabe A 33 1994 447 452
18. M. Menarini, G. Del Popolo, P. Di Benedetto TcP128-Study Group Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 44 2006 623 632
19. M. Stöhrer, P. Bauer, and B.M. Giannetti Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicentre placebo-controlled double-blind trial Urol Int 47 1991 138 143
20. M. Stöhrer, H. Madersbacher, and R. Richter Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - a double-blind, placebo-controlled clinical trial Spinal Cord 37 1999 196 200
21. M. Stöhrer, G. Mürtz, and G. Kramer Propiverine compared to oxybutynin in neurogenic detrusor overactivity - results of a randomized, double-blind, multicenter clinical study Eur Urol 51 2007 235 242
22. M. Stöhrer, G. Mürtz, and G. Kramer Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity International Continence Society abstract 432 2009
23. P.E. Van Kerrebroeck, G. Amarenco, and J.W. Thüroff Dose-ranging study of tolterodine in patients with detrusor hyperreflexia Neurourol Urodyn 17 1998 499 512
24. K. Lehtoranta, H. Tainio, and E. Lukkari-Lax Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity Scand J Urol Nephrol 36 2002 18 24
25. B. Ulshofer, A.-M. Bihr, and R.-H. Bodeker Randomised, double-blind, placebo-controlled study on the efficacy and tolerance of trospium chloride in patients with motor urge incontinence Clin Drug Invest 21 2001 563 569
26. J. Birns, E. Lukkari, and J.G. Malone-Lee A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin BJU Int 85 2000 793 798
27. J.M. Osca, A.E. Martinez, and S.J. Conejero Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders: a double blind randomised clinical trial [abstract 44] Br J Urol 80 Suppl 2 1997
28. M.J. Kennelly, G.E. Lemack, and J.E. Foote Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study Urology 74 2009 741 745
29. M. O'Leary, J.R. Erickson, and C.P. Smith Effect of controlled release oxybutynin on neurogenic bladder function in spinal cord injury J Spinal Cord Med 26 2003 159 162
30. M. Horstmann, T. Schaefer, and Y. Aguilar Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage Neurourol Urodyn 25 2006 441 445
31. A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10 mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity [identifier NCT00629642 ]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/ NCT00629642. Accessed December 2011.
32. Hassouna M. Comparative study of the efficacy and safety of muscarinic M3 receptors antagonists in the treatment of neurogenic detrusor overactivity [identifier NCT00800462 ]. ClinicalTrials.gov Web site. http://clinicaltrials. gov/show/NCT00800462. Accessed December 2011.
33. G. Nabi, J.D. Cody, and G. Ellis Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database Syst Rev 4 2006 CD003781
34. R.S. Nicholas, T. Friede, and S. Hollis Anticholinergics for urinary symptoms in multiple sclerosis Cochrane Database Syst Rev 1 2009 CD004193
35. C.R. Chapple, V. Khullar, and Z. Gabriel The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 2008 543 562
36. G. Novara, A. Galfano, and S. Secco A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder Eur Urol 54 2008 740 764
37. J. Hay-Smith, P. Herbison, G. Ellis, and A. Morris Which anticholinergic drug for overactive bladder symptoms in adults Cochrane Database Syst Rev 3 2005 CD005429
38. Stöhrer M, Mürtz G, Madersbacher H. Neurogenic detrusor overactivity in adults: a review of the efficacy, tolerability and safety of oral antimuscarinics [abstract 197]. Presented at: 3rd combined annual meeting of the International Continence Society and the International Urogynecological Association; August 23-27, 2010; Toronto, Canada.